Impacts of the 13-valent pneumococcal conjugate vaccine in children

Susanna Esposito, Nicola Principi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.

Original languageEnglish
Article number591580
JournalJournal of Immunology Research
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Conjugate Vaccines
Immunization Schedule
Vaccines
Serogroup
13-valent pneumococcal vaccine
Pediatrics
Incidence
Infection

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Impacts of the 13-valent pneumococcal conjugate vaccine in children. / Esposito, Susanna; Principi, Nicola.

In: Journal of Immunology Research, Vol. 2015, 591580, 2015.

Research output: Contribution to journalArticle

Esposito, Susanna ; Principi, Nicola. / Impacts of the 13-valent pneumococcal conjugate vaccine in children. In: Journal of Immunology Research. 2015 ; Vol. 2015.
@article{0dbf22422b94424aa8cad0aa42d6488b,
title = "Impacts of the 13-valent pneumococcal conjugate vaccine in children",
abstract = "Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.",
author = "Susanna Esposito and Nicola Principi",
year = "2015",
doi = "10.1155/2015/591580",
language = "English",
volume = "2015",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Impacts of the 13-valent pneumococcal conjugate vaccine in children

AU - Esposito, Susanna

AU - Principi, Nicola

PY - 2015

Y1 - 2015

N2 - Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.

AB - Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.

UR - http://www.scopus.com/inward/record.url?scp=84940880108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940880108&partnerID=8YFLogxK

U2 - 10.1155/2015/591580

DO - 10.1155/2015/591580

M3 - Article

VL - 2015

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 591580

ER -